FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ETV1-BTBD9

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ETV1-BTBD9
FusionPDB ID: 27680
FusionGDB2.0 ID: 27680
HgeneTgene
Gene symbol

ETV1

BTBD9

Gene ID

2115

114781

Gene nameETS variant transcription factor 1BTB domain containing 9
SynonymsER81dJ322I12.1
Cytomap

7p21.2

6p21.2

Type of geneprotein-codingprotein-coding
DescriptionETS translocation variant 1ETS variant 1ets variant gene 1ets-related protein 81BTB/POZ domain-containing protein 9BTB (POZ) domain containing 9
Modification date2020031320200313
UniProtAcc

P50549

Main function of 5'-partner protein: FUNCTION: Transcriptional activator that binds to DNA sequences containing the consensus pentanucleotide 5'-CGGA[AT]-3' (PubMed:7651741). Required for olfactory dopaminergic neuron differentiation; may directly activate expression of tyrosine hydroxylase (TH) (By similarity). {ECO:0000250|UniProtKB:P41164, ECO:0000269|PubMed:7651741}.

Q96Q07

Main function of 5'-partner protein:
Ensembl transtripts involved in fusion geneENST idsENST00000476720, ENST00000242066, 
ENST00000343495, ENST00000399357, 
ENST00000403527, ENST00000405192, 
ENST00000405218, ENST00000405358, 
ENST00000420159, ENST00000430479, 
ENST00000403685, 
ENST00000314100, 
ENST00000403056, ENST00000408958, 
ENST00000419706, ENST00000481247, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score3 X 3 X 2=1818 X 18 X 7=2268
# samples 320
** MAII scorelog2(3/18*10)=0.736965594166206
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
log2(20/2268*10)=-3.5033487351675
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ETV1 [Title/Abstract] AND BTBD9 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ETV1 [Title/Abstract] AND BTBD9 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ETV1(13971127)-BTBD9(38224292), # samples:3
Anticipated loss of major functional domain due to fusion event.ETV1-BTBD9 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ETV1-BTBD9 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ETV1-BTBD9 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF.
ETV1-BTBD9 seems lost the major protein functional domain in Hgene partner, which is a transcription factor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneETV1

GO:0045944

positive regulation of transcription by RNA polymerase II

12750007



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:13971127/chr6:38224292)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ETV1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across BTBD9 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000403685ETV1chr713971127-ENST00000314100BTBD9chr638224292-78829631911087298
ENST00000403685ETV1chr713971127-ENST00000481247BTBD9chr638224292-78829631911087298
ENST00000403685ETV1chr713971127-ENST00000419706BTBD9chr638224292-13749631911087298
ENST00000403685ETV1chr713971127-ENST00000408958BTBD9chr638224292-13489631911087298
ENST00000403685ETV1chr713971127-ENST00000403056BTBD9chr638224292-13489631911087298

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000403685ENST00000314100ETV1chr713971127-BTBD9chr638224292-0.0058246910.9941754
ENST00000403685ENST00000481247ETV1chr713971127-BTBD9chr638224292-0.0058246910.9941754
ENST00000403685ENST00000419706ETV1chr713971127-BTBD9chr638224292-0.0094404180.9905595
ENST00000403685ENST00000408958ETV1chr713971127-BTBD9chr638224292-0.0095762910.99042374
ENST00000403685ENST00000403056ETV1chr713971127-BTBD9chr638224292-0.0095762910.99042374

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ETV1-BTBD9

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ETV1chr713971127BTBD9chr638224292963256LMIKQEPRDFAYDSGYYFGIVMIEAI

Top

Potential FusionNeoAntigen Information of ETV1-BTBD9 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ETV1-BTBD9_13971127_38224292.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ETV1-BTBD9chr713971127chr638224292963HLA-B15:02FAYDSGYY0.99870.7872917
ETV1-BTBD9chr713971127chr638224292963HLA-B35:01FAYDSGYY0.99570.7335917
ETV1-BTBD9chr713971127chr638224292963HLA-B35:08FAYDSGYYF0.9980.7602918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:01FAYDSGYYF0.99750.7861918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:02FAYDSGYYF0.99730.8288918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:25FAYDSGYYF0.99670.8154918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:17FAYDSGYYF0.99570.764918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:16FAYDSGYYF0.99190.5522918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:03FAYDSGYYF0.98820.7674918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:01FAYDSGYYF0.98670.7985918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:03FAYDSGYYF0.97860.6482918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:18FAYDSGYYF0.97220.5936918
ETV1-BTBD9chr713971127chr638224292963HLA-B58:01FAYDSGYYF0.96980.7185918
ETV1-BTBD9chr713971127chr638224292963HLA-B58:02FAYDSGYYF0.94630.7526918
ETV1-BTBD9chr713971127chr638224292963HLA-B57:03FAYDSGYYF0.9420.8467918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:02FAYDSGYYF0.87380.8487918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:04FAYDSGYYF0.87380.8487918
ETV1-BTBD9chr713971127chr638224292963HLA-A32:13FAYDSGYYF0.84170.7724918
ETV1-BTBD9chr713971127chr638224292963HLA-B52:01FAYDSGYYF0.71010.8243918
ETV1-BTBD9chr713971127chr638224292963HLA-B13:01FAYDSGYYF0.4560.8131918
ETV1-BTBD9chr713971127chr638224292963HLA-B57:01RDFAYDSGYYF0.99790.9316718
ETV1-BTBD9chr713971127chr638224292963HLA-B57:03RDFAYDSGYYF0.99460.94718
ETV1-BTBD9chr713971127chr638224292963HLA-B58:02RDFAYDSGYYF0.99410.8016718
ETV1-BTBD9chr713971127chr638224292963HLA-B15:16RDFAYDSGYYF0.97620.6641718
ETV1-BTBD9chr713971127chr638224292963HLA-A32:13RDFAYDSGYYF0.97580.7277718
ETV1-BTBD9chr713971127chr638224292963HLA-B15:17RDFAYDSGYYF0.9680.8532718
ETV1-BTBD9chr713971127chr638224292963HLA-B58:01RDFAYDSGYYF0.96210.8023718
ETV1-BTBD9chr713971127chr638224292963HLA-C04:10AYDSGYYF0.99910.5391018
ETV1-BTBD9chr713971127chr638224292963HLA-C04:07AYDSGYYF0.99910.56321018
ETV1-BTBD9chr713971127chr638224292963HLA-B15:21FAYDSGYY0.99880.7668917
ETV1-BTBD9chr713971127chr638224292963HLA-C07:10AYDSGYYF0.99780.96151018
ETV1-BTBD9chr713971127chr638224292963HLA-C07:67AYDSGYYF0.99760.94191018
ETV1-BTBD9chr713971127chr638224292963HLA-C07:80AYDSGYYF0.99760.94191018
ETV1-BTBD9chr713971127chr638224292963HLA-C15:04FAYDSGYY0.99620.8471917
ETV1-BTBD9chr713971127chr638224292963HLA-C12:04FAYDSGYY0.99010.9879917
ETV1-BTBD9chr713971127chr638224292963HLA-C06:03FAYDSGYY0.98970.9849917
ETV1-BTBD9chr713971127chr638224292963HLA-C04:14AYDSGYYF0.98230.56111018
ETV1-BTBD9chr713971127chr638224292963HLA-C12:12FAYDSGYY0.98130.8894917
ETV1-BTBD9chr713971127chr638224292963HLA-C03:14FAYDSGYY0.95540.9659917
ETV1-BTBD9chr713971127chr638224292963HLA-C03:08FAYDSGYYF0.9980.7717918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:21FAYDSGYYF0.99750.8136918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:31FAYDSGYYF0.99730.7449918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:05FAYDSGYYF0.99710.7327918
ETV1-BTBD9chr713971127chr638224292963HLA-C12:16FAYDSGYYF0.99640.9535918
ETV1-BTBD9chr713971127chr638224292963HLA-C03:19FAYDSGYYF0.99410.9828918
ETV1-BTBD9chr713971127chr638224292963HLA-C15:04FAYDSGYYF0.99140.8311918
ETV1-BTBD9chr713971127chr638224292963HLA-C03:07FAYDSGYYF0.990.9718918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:07FAYDSGYYF0.98920.5541918
ETV1-BTBD9chr713971127chr638224292963HLA-C07:10FAYDSGYYF0.98890.9269918
ETV1-BTBD9chr713971127chr638224292963HLA-C07:80FAYDSGYYF0.98870.8635918
ETV1-BTBD9chr713971127chr638224292963HLA-C07:67FAYDSGYYF0.98870.8635918
ETV1-BTBD9chr713971127chr638224292963HLA-C07:29FAYDSGYYF0.9870.7942918
ETV1-BTBD9chr713971127chr638224292963HLA-C03:14FAYDSGYYF0.98330.9654918
ETV1-BTBD9chr713971127chr638224292963HLA-C07:27FAYDSGYYF0.98150.9053918
ETV1-BTBD9chr713971127chr638224292963HLA-C07:46FAYDSGYYF0.98010.6718918
ETV1-BTBD9chr713971127chr638224292963HLA-C07:05FAYDSGYYF0.97830.9076918
ETV1-BTBD9chr713971127chr638224292963HLA-C07:13FAYDSGYYF0.97780.8208918
ETV1-BTBD9chr713971127chr638224292963HLA-C15:06FAYDSGYYF0.97760.7805918
ETV1-BTBD9chr713971127chr638224292963HLA-C04:06FAYDSGYYF0.95470.5579918
ETV1-BTBD9chr713971127chr638224292963HLA-C12:12FAYDSGYYF0.94890.8878918
ETV1-BTBD9chr713971127chr638224292963HLA-C12:04FAYDSGYYF0.93320.9852918
ETV1-BTBD9chr713971127chr638224292963HLA-C06:03FAYDSGYYF0.92850.9771918
ETV1-BTBD9chr713971127chr638224292963HLA-C08:04FAYDSGYYF0.92220.9141918
ETV1-BTBD9chr713971127chr638224292963HLA-C08:13FAYDSGYYF0.92220.9141918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:12FAYDSGYYF0.87380.8487918
ETV1-BTBD9chr713971127chr638224292963HLA-C08:03FAYDSGYYF0.86820.9412918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:04FAYDSGYYF0.85160.7902918
ETV1-BTBD9chr713971127chr638224292963HLA-C05:09FAYDSGYYF0.78480.8772918
ETV1-BTBD9chr713971127chr638224292963HLA-B51:07FAYDSGYYF0.71190.7382918
ETV1-BTBD9chr713971127chr638224292963HLA-C02:06FAYDSGYYF0.68740.9644918
ETV1-BTBD9chr713971127chr638224292963HLA-C01:17FAYDSGYYF0.6320.8824918
ETV1-BTBD9chr713971127chr638224292963HLA-C08:15FAYDSGYYF0.6050.9183918
ETV1-BTBD9chr713971127chr638224292963HLA-C01:30FAYDSGYYF0.46970.9049918
ETV1-BTBD9chr713971127chr638224292963HLA-C03:14RDFAYDSGYYF0.99890.9409718
ETV1-BTBD9chr713971127chr638224292963HLA-C15:04RDFAYDSGYYF0.99770.798718
ETV1-BTBD9chr713971127chr638224292963HLA-C04:01AYDSGYYF0.99910.56321018
ETV1-BTBD9chr713971127chr638224292963HLA-C18:01AYDSGYYF0.99870.58631018
ETV1-BTBD9chr713971127chr638224292963HLA-B15:11FAYDSGYY0.99860.7867917
ETV1-BTBD9chr713971127chr638224292963HLA-B35:11FAYDSGYY0.99860.7556917
ETV1-BTBD9chr713971127chr638224292963HLA-B15:08FAYDSGYY0.99850.7848917
ETV1-BTBD9chr713971127chr638224292963HLA-B35:30FAYDSGYY0.99830.5083917
ETV1-BTBD9chr713971127chr638224292963HLA-B35:17FAYDSGYY0.99830.5083917
ETV1-BTBD9chr713971127chr638224292963HLA-B35:43FAYDSGYY0.99810.7814917
ETV1-BTBD9chr713971127chr638224292963HLA-C03:02FAYDSGYY0.99810.9465917
ETV1-BTBD9chr713971127chr638224292963HLA-C07:17AYDSGYYF0.99790.95481018
ETV1-BTBD9chr713971127chr638224292963HLA-C07:02AYDSGYYF0.99760.94191018
ETV1-BTBD9chr713971127chr638224292963HLA-C12:02FAYDSGYY0.9970.9616917
ETV1-BTBD9chr713971127chr638224292963HLA-B35:23FAYDSGYY0.99650.7467917
ETV1-BTBD9chr713971127chr638224292963HLA-C15:09FAYDSGYY0.99620.8471917
ETV1-BTBD9chr713971127chr638224292963HLA-B35:20FAYDSGYY0.9960.7605917
ETV1-BTBD9chr713971127chr638224292963HLA-B35:77FAYDSGYY0.99570.7335917
ETV1-BTBD9chr713971127chr638224292963HLA-C14:02AYDSGYYF0.99220.91941018
ETV1-BTBD9chr713971127chr638224292963HLA-C14:03AYDSGYYF0.99220.91941018
ETV1-BTBD9chr713971127chr638224292963HLA-C12:03FAYDSGYY0.990.9696917
ETV1-BTBD9chr713971127chr638224292963HLA-C04:04AYDSGYYF0.98570.66791018
ETV1-BTBD9chr713971127chr638224292963HLA-B35:24FAYDSGYY0.98310.8793917
ETV1-BTBD9chr713971127chr638224292963HLA-C16:04FAYDSGYY0.97740.9745917
ETV1-BTBD9chr713971127chr638224292963HLA-C16:02FAYDSGYY0.96160.9759917
ETV1-BTBD9chr713971127chr638224292963HLA-B18:07FAYDSGYY0.92610.7561917
ETV1-BTBD9chr713971127chr638224292963HLA-C02:10FAYDSGYY0.91650.973917
ETV1-BTBD9chr713971127chr638224292963HLA-C02:02FAYDSGYY0.91650.973917
ETV1-BTBD9chr713971127chr638224292963HLA-C16:01FAYDSGYY0.8780.963917
ETV1-BTBD9chr713971127chr638224292963HLA-C03:02FAYDSGYYF0.99890.9546918
ETV1-BTBD9chr713971127chr638224292963HLA-C03:04FAYDSGYYF0.99890.9813918
ETV1-BTBD9chr713971127chr638224292963HLA-C03:03FAYDSGYYF0.99890.9813918
ETV1-BTBD9chr713971127chr638224292963HLA-C03:67FAYDSGYYF0.99840.9654918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:77FAYDSGYYF0.99750.7861918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:20FAYDSGYYF0.99750.809918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:23FAYDSGYYF0.99740.7945918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:20FAYDSGYYF0.9970.8175918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:11FAYDSGYYF0.99690.8004918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:28FAYDSGYYF0.99680.803918
ETV1-BTBD9chr713971127chr638224292963HLA-C12:02FAYDSGYYF0.99620.9642918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:30FAYDSGYYF0.99610.5915918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:17FAYDSGYYF0.99610.5915918
ETV1-BTBD9chr713971127chr638224292963HLA-C16:04FAYDSGYYF0.99450.9771918
ETV1-BTBD9chr713971127chr638224292963HLA-C03:05FAYDSGYYF0.99410.8861918
ETV1-BTBD9chr713971127chr638224292963HLA-C03:17FAYDSGYYF0.99360.9464918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:39FAYDSGYYF0.99310.7044918
ETV1-BTBD9chr713971127chr638224292963HLA-C15:09FAYDSGYYF0.99140.8311918
ETV1-BTBD9chr713971127chr638224292963HLA-C07:17FAYDSGYYF0.99130.9455918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:24FAYDSGYYF0.99050.8351918
ETV1-BTBD9chr713971127chr638224292963HLA-C07:22FAYDSGYYF0.98990.5288918
ETV1-BTBD9chr713971127chr638224292963HLA-B48:02FAYDSGYYF0.98940.769918
ETV1-BTBD9chr713971127chr638224292963HLA-C07:02FAYDSGYYF0.98870.8635918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:11FAYDSGYYF0.98820.7625918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:08FAYDSGYYF0.98810.7669918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:50FAYDSGYYF0.98790.7953918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:13FAYDSGYYF0.98750.7705918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:33FAYDSGYYF0.98670.7985918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:125FAYDSGYYF0.98670.7985918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:34FAYDSGYYF0.98670.7985918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:27FAYDSGYYF0.98620.8203918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:135FAYDSGYYF0.98510.7877918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:24FAYDSGYYF0.98450.7727918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:43FAYDSGYYF0.98370.7626918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:53FAYDSGYYF0.98080.7681918
ETV1-BTBD9chr713971127chr638224292963HLA-B57:02FAYDSGYYF0.98030.7084918
ETV1-BTBD9chr713971127chr638224292963HLA-C12:03FAYDSGYYF0.98020.9732918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:12FAYDSGYYF0.97940.7409918
ETV1-BTBD9chr713971127chr638224292963HLA-C16:01FAYDSGYYF0.9790.9685918
ETV1-BTBD9chr713971127chr638224292963HLA-C07:04FAYDSGYYF0.9760.7714918
ETV1-BTBD9chr713971127chr638224292963HLA-B58:06FAYDSGYYF0.97390.5998918
ETV1-BTBD9chr713971127chr638224292963HLA-A25:01FAYDSGYYF0.96980.7481918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:35FAYDSGYYF0.96750.7761918
ETV1-BTBD9chr713971127chr638224292963HLA-C15:05FAYDSGYYF0.96090.8426918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:54FAYDSGYYF0.95580.7535918
ETV1-BTBD9chr713971127chr638224292963HLA-C15:02FAYDSGYYF0.9510.8161918
ETV1-BTBD9chr713971127chr638224292963HLA-C06:02FAYDSGYYF0.94540.9846918
ETV1-BTBD9chr713971127chr638224292963HLA-C06:17FAYDSGYYF0.94540.9846918
ETV1-BTBD9chr713971127chr638224292963HLA-C03:06FAYDSGYYF0.94510.981918
ETV1-BTBD9chr713971127chr638224292963HLA-C06:06FAYDSGYYF0.89460.978918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:09FAYDSGYYF0.87380.8487918
ETV1-BTBD9chr713971127chr638224292963HLA-C08:01FAYDSGYYF0.86820.9412918
ETV1-BTBD9chr713971127chr638224292963HLA-B18:04FAYDSGYYF0.85560.7754918
ETV1-BTBD9chr713971127chr638224292963HLA-C16:02FAYDSGYYF0.84060.9771918
ETV1-BTBD9chr713971127chr638224292963HLA-B15:30FAYDSGYYF0.80810.6618918
ETV1-BTBD9chr713971127chr638224292963HLA-C04:03FAYDSGYYF0.79470.5802918
ETV1-BTBD9chr713971127chr638224292963HLA-C05:01FAYDSGYYF0.78480.8772918
ETV1-BTBD9chr713971127chr638224292963HLA-C14:03FAYDSGYYF0.77310.9212918
ETV1-BTBD9chr713971127chr638224292963HLA-C14:02FAYDSGYYF0.77310.9212918
ETV1-BTBD9chr713971127chr638224292963HLA-C18:01FAYDSGYYF0.76440.5454918
ETV1-BTBD9chr713971127chr638224292963HLA-C02:10FAYDSGYYF0.74970.9719918
ETV1-BTBD9chr713971127chr638224292963HLA-C02:02FAYDSGYYF0.74970.9719918
ETV1-BTBD9chr713971127chr638224292963HLA-B78:02FAYDSGYYF0.74020.553918
ETV1-BTBD9chr713971127chr638224292963HLA-B18:07FAYDSGYYF0.66580.7368918
ETV1-BTBD9chr713971127chr638224292963HLA-C01:02FAYDSGYYF0.64780.8826918
ETV1-BTBD9chr713971127chr638224292963HLA-C08:02FAYDSGYYF0.6050.9183918
ETV1-BTBD9chr713971127chr638224292963HLA-C06:08FAYDSGYYF0.59870.9831918
ETV1-BTBD9chr713971127chr638224292963HLA-B18:08FAYDSGYYF0.58140.5496918
ETV1-BTBD9chr713971127chr638224292963HLA-B07:13FAYDSGYYF0.4230.753918
ETV1-BTBD9chr713971127chr638224292963HLA-C17:01FAYDSGYYF0.2910.5941918
ETV1-BTBD9chr713971127chr638224292963HLA-B35:24DFAYDSGYYF0.96830.7339818
ETV1-BTBD9chr713971127chr638224292963HLA-A25:01DFAYDSGYYF0.84040.6808818
ETV1-BTBD9chr713971127chr638224292963HLA-C02:02RDFAYDSGYYF0.9990.9362718
ETV1-BTBD9chr713971127chr638224292963HLA-C02:10RDFAYDSGYYF0.9990.9362718
ETV1-BTBD9chr713971127chr638224292963HLA-B57:10RDFAYDSGYYF0.99790.9316718
ETV1-BTBD9chr713971127chr638224292963HLA-C15:09RDFAYDSGYYF0.99770.798718
ETV1-BTBD9chr713971127chr638224292963HLA-B57:04RDFAYDSGYYF0.99260.6396718
ETV1-BTBD9chr713971127chr638224292963HLA-B57:02RDFAYDSGYYF0.9920.8541718
ETV1-BTBD9chr713971127chr638224292963HLA-B58:06RDFAYDSGYYF0.99180.6533718
ETV1-BTBD9chr713971127chr638224292963HLA-A32:01RDFAYDSGYYF0.98080.6881718

Top

Potential FusionNeoAntigen Information of ETV1-BTBD9 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ETV1-BTBD9_13971127_38224292.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ETV1-BTBD9chr713971127chr638224292963DRB1-0338EPRDFAYDSGYYFGI520
ETV1-BTBD9chr713971127chr638224292963DRB1-0338PRDFAYDSGYYFGIV621
ETV1-BTBD9chr713971127chr638224292963DRB1-0338QEPRDFAYDSGYYFG419
ETV1-BTBD9chr713971127chr638224292963DRB1-1222PRDFAYDSGYYFGIV621
ETV1-BTBD9chr713971127chr638224292963DRB1-1222EPRDFAYDSGYYFGI520
ETV1-BTBD9chr713971127chr638224292963DRB3-0101EPRDFAYDSGYYFGI520
ETV1-BTBD9chr713971127chr638224292963DRB3-0101PRDFAYDSGYYFGIV621
ETV1-BTBD9chr713971127chr638224292963DRB3-0101QEPRDFAYDSGYYFG419
ETV1-BTBD9chr713971127chr638224292963DRB3-0101RDFAYDSGYYFGIVM722
ETV1-BTBD9chr713971127chr638224292963DRB3-0101KQEPRDFAYDSGYYF318
ETV1-BTBD9chr713971127chr638224292963DRB3-0104EPRDFAYDSGYYFGI520
ETV1-BTBD9chr713971127chr638224292963DRB3-0104PRDFAYDSGYYFGIV621
ETV1-BTBD9chr713971127chr638224292963DRB3-0104QEPRDFAYDSGYYFG419
ETV1-BTBD9chr713971127chr638224292963DRB3-0104RDFAYDSGYYFGIVM722
ETV1-BTBD9chr713971127chr638224292963DRB3-0104KQEPRDFAYDSGYYF318
ETV1-BTBD9chr713971127chr638224292963DRB3-0105EPRDFAYDSGYYFGI520
ETV1-BTBD9chr713971127chr638224292963DRB3-0105PRDFAYDSGYYFGIV621
ETV1-BTBD9chr713971127chr638224292963DRB3-0105QEPRDFAYDSGYYFG419
ETV1-BTBD9chr713971127chr638224292963DRB3-0105RDFAYDSGYYFGIVM722
ETV1-BTBD9chr713971127chr638224292963DRB3-0105KQEPRDFAYDSGYYF318
ETV1-BTBD9chr713971127chr638224292963DRB3-0108EPRDFAYDSGYYFGI520
ETV1-BTBD9chr713971127chr638224292963DRB3-0108PRDFAYDSGYYFGIV621
ETV1-BTBD9chr713971127chr638224292963DRB3-0108QEPRDFAYDSGYYFG419
ETV1-BTBD9chr713971127chr638224292963DRB3-0108RDFAYDSGYYFGIVM722
ETV1-BTBD9chr713971127chr638224292963DRB3-0108KQEPRDFAYDSGYYF318
ETV1-BTBD9chr713971127chr638224292963DRB3-0109EPRDFAYDSGYYFGI520
ETV1-BTBD9chr713971127chr638224292963DRB3-0109PRDFAYDSGYYFGIV621
ETV1-BTBD9chr713971127chr638224292963DRB3-0109QEPRDFAYDSGYYFG419
ETV1-BTBD9chr713971127chr638224292963DRB3-0111EPRDFAYDSGYYFGI520
ETV1-BTBD9chr713971127chr638224292963DRB3-0111PRDFAYDSGYYFGIV621
ETV1-BTBD9chr713971127chr638224292963DRB3-0111QEPRDFAYDSGYYFG419
ETV1-BTBD9chr713971127chr638224292963DRB3-0111RDFAYDSGYYFGIVM722
ETV1-BTBD9chr713971127chr638224292963DRB3-0111KQEPRDFAYDSGYYF318
ETV1-BTBD9chr713971127chr638224292963DRB3-0112EPRDFAYDSGYYFGI520
ETV1-BTBD9chr713971127chr638224292963DRB3-0112PRDFAYDSGYYFGIV621
ETV1-BTBD9chr713971127chr638224292963DRB3-0112QEPRDFAYDSGYYFG419
ETV1-BTBD9chr713971127chr638224292963DRB3-0112RDFAYDSGYYFGIVM722
ETV1-BTBD9chr713971127chr638224292963DRB3-0112KQEPRDFAYDSGYYF318
ETV1-BTBD9chr713971127chr638224292963DRB3-0113EPRDFAYDSGYYFGI520
ETV1-BTBD9chr713971127chr638224292963DRB3-0113PRDFAYDSGYYFGIV621
ETV1-BTBD9chr713971127chr638224292963DRB3-0113QEPRDFAYDSGYYFG419
ETV1-BTBD9chr713971127chr638224292963DRB3-0113RDFAYDSGYYFGIVM722
ETV1-BTBD9chr713971127chr638224292963DRB3-0113KQEPRDFAYDSGYYF318
ETV1-BTBD9chr713971127chr638224292963DRB3-0114EPRDFAYDSGYYFGI520
ETV1-BTBD9chr713971127chr638224292963DRB3-0114PRDFAYDSGYYFGIV621
ETV1-BTBD9chr713971127chr638224292963DRB3-0114QEPRDFAYDSGYYFG419
ETV1-BTBD9chr713971127chr638224292963DRB3-0114RDFAYDSGYYFGIVM722
ETV1-BTBD9chr713971127chr638224292963DRB3-0303PRDFAYDSGYYFGIV621
ETV1-BTBD9chr713971127chr638224292963DRB3-0303EPRDFAYDSGYYFGI520

Top

Fusion breakpoint peptide structures of ETV1-BTBD9

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
6937PRDFAYDSGYYFGIETV1BTBD9chr713971127chr638224292963

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ETV1-BTBD9

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN6937PRDFAYDSGYYFGI-4.6399-4.7533
HLA-B14:023BVN6937PRDFAYDSGYYFGI-3.07499-4.11029
HLA-B52:013W396937PRDFAYDSGYYFGI-5.4302-5.5436
HLA-B52:013W396937PRDFAYDSGYYFGI-1.43817-2.47347
HLA-A24:025HGA6937PRDFAYDSGYYFGI-9.56215-9.67555
HLA-A24:025HGA6937PRDFAYDSGYYFGI-6.57158-7.60688
HLA-B44:053DX86937PRDFAYDSGYYFGI-7.1898-7.3032
HLA-B44:053DX86937PRDFAYDSGYYFGI-5.49669-6.53199
HLA-A02:016TDR6937PRDFAYDSGYYFGI-6.78343-6.89683

Top

Vaccine Design for the FusionNeoAntigens of ETV1-BTBD9

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ETV1-BTBD9chr713971127chr6382242921018AYDSGYYFATGACTCAGGTTACTACTTTGGGA
ETV1-BTBD9chr713971127chr638224292718RDFAYDSGYYFATTTTGCATATGACTCAGGTTACTACTTTGGGA
ETV1-BTBD9chr713971127chr638224292818DFAYDSGYYFTTGCATATGACTCAGGTTACTACTTTGGGA
ETV1-BTBD9chr713971127chr638224292917FAYDSGYYCATATGACTCAGGTTACTACTTTG
ETV1-BTBD9chr713971127chr638224292918FAYDSGYYFCATATGACTCAGGTTACTACTTTGGGA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ETV1-BTBD9chr713971127chr638224292318KQEPRDFAYDSGYYFAGGAACCCAGAGATTTTGCATATGACTCAGGTTACTACTTTGGGA
ETV1-BTBD9chr713971127chr638224292419QEPRDFAYDSGYYFGAACCCAGAGATTTTGCATATGACTCAGGTTACTACTTTGGGATTG
ETV1-BTBD9chr713971127chr638224292520EPRDFAYDSGYYFGICCAGAGATTTTGCATATGACTCAGGTTACTACTTTGGGATTGTGA
ETV1-BTBD9chr713971127chr638224292621PRDFAYDSGYYFGIVGAGATTTTGCATATGACTCAGGTTACTACTTTGGGATTGTGATGA
ETV1-BTBD9chr713971127chr638224292722RDFAYDSGYYFGIVMATTTTGCATATGACTCAGGTTACTACTTTGGGATTGTGATGATCG

Top

Information of the samples that have these potential fusion neoantigens of ETV1-BTBD9

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
SARCETV1-BTBD9chr713971127ENST00000403685chr638224292ENST00000314100TCGA-FX-A2QS-01A

Top

Potential target of CAR-T therapy development for ETV1-BTBD9

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ETV1-BTBD9

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ETV1-BTBD9

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneETV1C0033578Prostatic Neoplasms3CTD_human
HgeneETV1C0376358Malignant neoplasm of prostate3CTD_human
HgeneETV1C0009402Colorectal Carcinoma1CTD_human
HgeneETV1C0009404Colorectal Neoplasms1CTD_human